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Minute virus of mice (MVM) infection is disrupted by proteasome inhibitors. Here, we show that inhibition of the ubiquitin–proteasome
pathway did not affect viral entry and had influence neither on the natural proteolytic cleavage of VP2 to VP3 nor on the externalization of
the N terminal of VP1. In both MG132-treated and untreated cells, MVM particles accumulated progressively in the perinuclear region.
However, in MG132-treated cells, MVM was not able to penetrate into the nuclei, remaining blocked in the perinuclear region without capsid
disassembly. MVM was similarly sensitive to MG132 in the two cell lines tested, A9 and NB324K. After releasing from the reversible
MG132 block, MVM recovered the ability to translocate to the nuclei and replicate. Analysis of viral capsid proteins during internalization
showed no evidence of capsid ubiquitination or degradation. We examined the effect of MG132 on two other parvoviruses, canine (CPV) and
bovine parvovirus (BPV). Similarly to MVM, CPV infection was sensitive to MG132; however, BPV infection, as previously shown for
adeno-associated viruses (AAVs), was not disturbed. These findings suggest that parvoviruses follow divergent strategies for nuclear
transport, some of them requiring active proteasomes.
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Introduction VP1 protein, which might be responsible for parvovirusMinute virus of mice (MVM) is a small, nonenveloped,
and icosahedral parvovirus that replicates in the nucleus of
actively dividing cells (Cotmore and Tattersall, 1987). The
genome consists of a linear, single-stranded DNA of ap-
proximately 5 kb organized into two overlapping transcrip-
tion units. The left-hand unit, driven by the P4 promoter,
encodes the nonstructural proteins NS1 and NS2, and the
right-hand unit, driven by the P38 promoter, encodes the
structural proteins VP1 and VP2 (Clemens and Pintel, 1988).
The cytoplasmic trafficking of MVM involves the endo-
somal network. We have previously shown that MVM
entry involves a low pH-dependent entry pathway and that
escape from the endosomal network is slow (Ros et al.,
2002). Phospholipase A2 motifs have been found in the0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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2001), although it has been recently shown that there
should be other factors involved (Suikkanen et al., 2003).
The process by which the viral particles, once released into
the cytoplasm, translocate to the nucleus remains unknown.
There are nuclear localization signals present in VP1 and
VP2 sequences (Lombardo et al., 2000; Tullis et al., 1993),
which are thought to be essential for the transport of the
intact or partially uncoated capsids to the nucleus for viral
replication (Vihinen-Ranta et al., 1997, 2000, 2002). It is
also known that components of the cytoskeleton are re-
quired (Ros et al., 2002; Vihinen-Ranta et al., 1998).
During the cytosolic trafficking, adeno-associated viruses
(AAVs) are degraded by the cellular proteasome machinery
(Douar et al., 2001; Duan et al., 2000; Yan et al., 2002).
Consequently, under proteasome blocking conditions, a
significant enhancement of recombinant AAV transduction
was observed. In addition, it was found that AAV-2 and -5
capsids are ubiquitinated during the infection (Yan et al.,
2002). These observations gave rise to the hypothesis that
Fig. 1. Effect of proteasome inactivation at increasing periods of time after
internalization. A9 cells (105) were infected with MVM at an MOI of 1000
DNA-containing particles/cell. Proteasomes were blocked at the indicated
times by the reversible MG132 (25 AM). The cells were washed to remove
the drug and further incubated until 18 h. Total DNA was extracted and
MVM genome copies were detected and quantified by real-time PCR.
Values represent the mean of three independent experiments. nt, not treated.
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transduction as they degrade a large proportion of AAV
incoming particles. We have previously shown that differ-
ently to AAVs, proteasome inhibitors abolished MVM
infection (Ros et al., 2002).
The interrelationships between proteasomes and viruses
are very complex. Proteasomes do not always represent a
degradative factor for viruses. There are various examples
of unrelated viruses in which the proteasomes are required
during the replication cycle. Some retroviruses, such as
human immunodeficiency virus, require the proteasome for
budding from cells. In contrast, the release of other
retroviruses like equine infectious anemia virus or mouse
mammary tumor virus does not require the proteasomes
(Ott et al., 2002, 2003; Patnaik et al., 2000, 2002; Schubert
et al., 2000; Strack et al., 2000). For HIV-1 and -2, the
processing of the Gag polyprotein into its mature proteins
by the viral protease is also reduced when it is produced
from cells with inactivated proteasomes (Schubert et al.,
2000). There are various examples of viruses that modulate
proteasome activity for their own benefits. Those modu-
lations are carried out by viral gene products. The human
cytomegalovirus pp71 protein stimulates quiescent cells to
enter the cell cycle by targeting the hypophosphorylated
forms of the Rb family for proteasome-dependent degra-
dation inducing cell cycle progression (Kalejta and Shenk,
2003; Kalejta et al., 2003). The V protein of simian virus 5
and human parainfluenza virus type 2 blocks IFN signaling
by targeting STAT1 or STAT2 (host cell transcription
factors essential for both IFN-a/h and IFN-g signaling)
for proteasome-mediated degradation (Andrejeva et al.,
2002; Didcock et al., 1999). Three viral proteins of
Epstein–Barr virus, the nuclear antigen 1 and the latent
membrane proteins-1 and -2A, regulate viral latency by
manipulating ubiquitin-dependent proteolysis (Dantuma
and Masucci, 2003). The proteasome activity is important
for the establishment of latency of herpes simplex virus 1
in neuronal cells (Eom and Lehman, 2003). Adenovirus
E4-34 kDa requires active proteasomes to promote late
gene expression (Corbin-Lickfett and Bridge, 2003). Pro-
teasome inhibition reduces coxsackievirus replication
through inhibition of viral RNA transcription and protein
synthesis (Luo et al., 2003).
Using Western blotting, real-time PCR, and immunoflu-
orescence microscopy, we have studied the role of the
proteasomes in MVM infection. In MG132-treated cells,
MVM virions move through the cytoplasm and gather as
intact particles in the perinuclear region in a way similar to
that of untreated cells, including the cleavage of VP2 to VP3
and the externalization of the N-terminal of VP1. However,
in cells with inactive proteasomes, the perinuclear intact
particles form aggregates without sings of capsid ubiquiti-
nation or degradation. From this point, the virions do not
progress and the infection is blocked. Similarly to MVM,
CPV but not BPV is sensitive to MG132, suggesting that
CPVand MVM have a similar nuclear translocation strategyinvolving the ubiquitin–proteasome machinery, which
clearly differs from that of AAV and BPV.Results
MVM requires the activity of the proteasomes early after
internalization
To clarify the role of the proteasomes in MVM infection,
it was important to elucidate whether they are required early
or late after viral internalization. We have previously shown
in asynchronized A9 cells that MVM-DNA replication starts
only 8–10 h after internalization, and that MVM endosomal
trafficking is slow and can take up to 6–8 h to be complete
for the bulk of viral particles (Ros et al., 2002). Therefore, if
the proteasomes were required during the first hours of
internalization, it would point out to a role during the
cytoplasmic trafficking and before nuclear translocation
and most probably involving the cytoplasmic proteasomes.
A late requirement would point out to a role in MVM
nuclear activity, like final steps of the uncoating process,
replication, and transcription. To address this question, A9
cells were infected with MVM and MG132 (25 AM) was
added and kept in the media for three different intervals, as
shown in Fig. 1. The cells were incubated until 18 h post-
infection, collected, and their total DNA extracted as spec-
ified in Materials and methods. Real-time PCR was used to
quantify the amount of viral DNA. The results showed that
MG132 was more efficient in blocking the infection when
present during the first interval after internalization (t = 0–6
h). In contrast, a very limited effect was observed when
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ering this result, it can be assumed that the requirement of
the proteasomes is linked to the cytoplasmic trafficking of
the virus and involving the cytosolic proteasomes.
Proteasomes are involved neither in VP2 proteolytic
processing nor in the externalization of the N-terminal of
VP1
During the cytoplasmic trafficking of MVM, two poorly
characterized viral protein modifications occur, namely the
cleavage of the N-terminal of VP2 and the externalization of
the N-terminal of VP1. Because the 26S proteasome is
involved not only in protein degradation but also in the
proteolytic processing of proteins (Rape and Jentsch,
2002), it was therefore reasonable to investigate the potential
role of the proteasomes in these two events. A9 cells were
infected with MVM without detectable levels of VP3 (Fig.
2A) with and without MG132 (25 AM) as indicated above.
After 5 h, cells were lysed in protein loading buffer and the
proteins were resolved by SDS-PAGE. The results showed
that the proteasome inhibitor MG132 did not prevent the
cleavage of VP2 to VP3 (Fig. 2A). Because the virus used to
infect the cells contained both full and empty capsids, a
proportion of VP2 was not processed. To confirm this result,Fig. 2. Effect of proteasome inactivation on VP2 cleavage and N-VP1 externalizat
containing particles/cell in the presence or absence of 25 AM MG132. At 0 and 5
SDS-PAGE and detected with a rabbit anti-VPs polyclonal antibody (1:2000 diluti
capsids without detectable levels of VP2 generated by in vitro cleavage with chym
A9 cells with and without MG132 (lanes 3 and 4); MVM from lane 2 (VP2 negativ
CHT; chymotrypsin. (C) A9 cells (105) were infected with MVM at an MOI of 5
were fixed 10 min and 8 h after infection in a methanol–acetone solution (1:1) and
B7; 1:200 dilution, in green) and a rabbit antibody against the N-terminal of VPthe VP2 cleavage was mimicked in vitro by digesting MVM-
purified full capsids, without detectable levels of VP3, with
a-chymotrypsin. The resulting viral capsids had only VP1
and VP3 proteins (Fig. 2B). The sensitivity of precleaved
(VP1/VP3) and uncleaved (VP1/VP2) viral particles to
MG132 was analyzed and compared. As it is shown in Fig.
2B, both viruses were similarly sensitive to MG132 and
similarly infectious in untreated cells. These results indicated
that the cellular proteasomes play no role in the natural
cleavage of VP2 to VP3.
In addition, the possible role of proteasomes in the
externalization of the N-terminal of VP1 was investigated.
A double immunostaining experiment with an antibody
against intact capsids (MAb B7) and an antibody against
the N-terminal of VP1 was performed on MG132-treated
cells. As it is shown in Fig. 2C, the N-terminal of VP1, which
was not exposed 10 min after the infection, became exposed
and accessible for the antibody at 8 h post-infection.
Proteasome inactivation blocks the nuclear penetration of
MVM particles
To clarify the reasons for the blocking effect of MG132
in MVM infection, the intracellular distribution of MVM
particles in A9 cells treated with MG132 was analyzed byion. (A) A9 cells (105) were infected with MVM at an MOI of 1000 DNA-
h after infection, cells were lysed and viral proteins were resolved by 10%
on). (B) MVM capsids without detectable levels of VP3 (lane 1); MVM full
otrypsin (lane 2); MVM from lane 1 (VP3 negative) after 24 h infection in
e) after 24 h infection in A9 cells with and without MG132 (lanes 5 and 6).
000 DNA-containing particles/cell in the presence of 25 AM MG132. Cells
stained with a mouse anti-capsid (detecting intact capsids) antibody (MAb
1 (1:100 dilution, in red).
C. Ros, C. Kempf / Virology 324 (2004) 350–360 353immunostaining and compared to untreated cells. In treated
cells, MVM was able to internalize and to reach a
perinuclear region with no difference to untreated cells,
from the scattered distribution at 30 min post-infection to a
polar perinuclear accumulation 4 h after infection. How-
ever, in MG132-treated cells, MVM was unable to pene-
trate into the nuclei and remained blocked in the
perinuclear region (Fig. 3A). The strong signal observedFig. 3. Subcellular distribution of MVM under natural and proteasome
blocking conditions. (A) Cells were infected with MVM in the presence
or absence of 25 AM MG132. At different times, cells were washed,
fixed, and stained with an antibody against MVM structural proteins
(anti-VPs; 1:200 dilution, in green). (B) A9 cells were infected with
MVM, treated with MG132, and fixed as indicated above. A double
immunostaining was performed with a rabbit anti-VPs (1:200 dilution,
in green) and a mouse antibody against early endosomes (EEA1; 1:100
dilution, in red) or a rat antibody against late endosomes or lysosomes
(Lamp2; 1:200 dilution, in red).at 24 h post-infection in untreated cells reflects the
expected emergence of progeny virions. To exclude that
the observed blocking effect of MG132 on MVM infection
is due to a direct effect on the capsids by MG132 and not
to the inactivation of the proteasomes, two other protea-
some inhibitors, epoxomicin (15 AM) and aclarubicin (0.5
AM), were used. The results showed that both proteasome
inhibitors were similarly able to block the nuclear pene-
tration of MVM (data not shown). Because it was observed
that in many cells, MVM appeared in a perinuclear polar
region of the cytoplasm, resembling that of the Golgi
apparatus, the possible colocalization of MVM and Golgi
was investigated in A9 cells. Double immunostaining with
an antibody against MVM VPs and an antibody against
giantin (marker for the Golgi apparatus) did not show any
area of colocalization after 3 and 8 h of internalization
neither in cells treated with MG132 nor in untreated cells
(data not shown).
The localization of MVM concerning endosomal vesicles
in MG132-treated cells was examined. A double-labeling
immunofluorescence analysis with an antibody against
MVM and an antibody against EEA1, used as marker for
early endosomes, and Lamp2, used as marker for late endo-
somes and lysosomes, was performed. The results showed
that 24 h p.i. MVM did not colocalize with any of the two
endosomal or lysosomal markers (Fig. 3B).
MVM incoming particles remain intact after 8 h
post-internalization in both untreated and
MG132-treated cells
With the aim of elucidating if the accumulated perinu-
clear particles are still intact or otherwise partially or totally
uncoated, a double immunostaining experiment with a
polyclonal antibody against MVM capsid proteins (VPs)
and a monoclonal antibody against intact capsids (MAb B7)
was performed. MAb B7 specifically recognizes MVM
intact capsids as previously demonstrated by different im-
munological tests (Lombardo et al., 2000; Lopez-Bueno et
al., 2003). We also tested the differential reactivity of these
two antibodies in our studies. As it is shown in Fig. 4A, at
24 h post-infection in untreated cells, antibody B7 only
recognizes the newly assembled particles inside the nuclei,
although antibody against MVM VPs recognizes the assem-
bled nuclear particles as well as the newly synthesized viral
capsid proteins in the cytosol. Double immunostaining with
these two antibodies at 8 h of internalization showed that
MVM particles accumulated as intact particles in a perinu-
clear region in both untreated and MG132-treated cells (Fig.
4B). Interestingly, in MG132-treated cells, MVM intact
particles were grouped around the nuclei as ring-like aggre-
gates (Fig. 4B). Similar aggregates were also present in
untreated cells but to a much lesser extent. In all cases, the
rings were not present at the beginning of the infection, but
became increasingly evident with the progression of the
internalization (data not shown). Fig. 4C shows that the
Fig. 4. Intact MVM particles accumulate around the nuclei at 8 h post-infection and aggregate in ring-like structures in MG132-treated cells. A9 cells were
infected with MVM, fixed, and stained with a rabbit antibody against MVM structural proteins (anti-VPs) or a mouse antibody against intact capsids (anti-
capsids). (A) Double immunostaining with anti-VPs (detecting structural proteins) and anti-capsid (detecting intact capsids) antibodies showing their
differential reactivity, 24 h after infection in nontreated cells. (B) Nontreated and MG132-treated cells, 8 h after infection showing the perinuclear accumulation
and the ring-like aggregates (C) Merge picture of anti-VPs, in green, anti-intact capsids, in red, and phase-contrast of an MG132-treated cell 8 h after infection,
revealing the perinuclear accumulation of MVM.
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side of the nuclear membrane.
The effect of MG132 on nuclear translocation of MVM is
reversible
The action of MG132 on the proteasome can be fully
reversed within 1 h after the withdrawal of the compound
(Coux et al., 1996; Palombella et al., 1994). As to ascertain
whether the effect of MG132 on MVM nuclear transloca-
tion can also be reversible, the drug was removed 8 h after
MVM internalization and the incubation continued in
MG132-free media until 24 h. Western blot analysis of
MVM structural proteins after MG132 release showed theprogressive recovery of MVM infection from 18 to 30
h post-infection (Fig. 5A). Double immunostaining with
anti-VP and anti-capsid antibodies showed that in cells
where MG132 was removed, MVM gained the ability to
translocate to the nuclei and replicate. However, when
MG132 was kept in the media, MVM did not penetrate
into the nuclei remaining as intact particles in the perinu-
clear region (Fig. 5B). The recovery of the proteasome
activity after withdrawal of MG132 was verified by ana-
lyzing the amount of the accumulated polyubiquitinated
cellular proteins. Interestingly, polyubiquitinated proteins
increased progressively up to 4 h after MG132 withdrawal,
and subsequently decreased slowly reaching control levels
by 24 h post-release (Fig. 5C).
Fig. 5. The effect of MG132 on nuclear translocation of MVM is reversible. MG132 (25 Am) was removed 8 h post-infection and the incubation continued in
MG132-free media. At various times after MG132-release, viral proteins were examined by Western blot (A) and immunofluorescence microscopy (B). (C)
The recovery of proteasome activity after MG132 withdrawal was verified by detecting the amount of accumulated polyubiquitinated proteins at progressive
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during the intracellular trafficking
Proteins to be targeted to the proteasome are polyubi-
quitinated by the covalent attachment of ubiquitin. Mono-
ubiquitination regulates internalization of receptors and
endosomal sorting. However, there are few examples of
proteins that target the proteasome by an ubiquitin-
independent pathway (Asher et al., 2002; Kalejta and Shenk,
2003; Krappmann et al., 1996; Michalek et al., 1996; Miller
times. NT; nontreated.and Pintel, 2001; Sheaff et al., 2000). We examined the
possibility that MVM capsid proteins are ubiquitinated
during the cytoplasmic trafficking of the virus. Immunopre-
cipitation experiments with an antibody against MVM VPs
and Western blot with an antibody against ubiquitin (P4D1)
did not demonstrate that capsid proteins from MVM were
ubiquitinated in A9 cells treated with MG132 (Fig. 6A). The
massive accumulation of polyubiquitinated protein conju-
gates observed in Fig. 6A demonstrates that the MG132-
treatment effectively inactivated the proteasome function. In
Fig. 6. MVM incoming capsids are neither ubiquitinated nor degraded
during the cytoplasmic trafficking. (A) Detection of ubiquitin in samples
immunoprecipitated with anti-VPs (lanes 1 and 2) and in total cell lysates
(lanes 3 and 4). (B) Analysis of viral structural proteins in the presence and
absence of MG132 at increasing periods of time after internalization.
Fig. 7. Effect of proteasome inactivation on different cell lines and parvovirus
infections. All cells were infected at an MOI of 1000 DNA-containing
particles/cell in the presence or absence of 25 AMMG132. At 4 and 8 h post-
infection, the cells were washed to remove the drug and further incubated
until 18 h for MVM-infected cells or until 24 h for CPV and BPV-infected
cells. Total DNAwas extracted and MVM genome copies were detected and
quantified by real-time PCR. (A) Proteasome inactivation disrupts MVM
infection on A9 and NB324K cells. (B) CPV but not BPV is sensitive to
MG132. Values represent the mean of three independent experiments.
C. Ros, C. Kempf / Virology356addition, if virions would be ubiquitinated, then one would
expect that treatment with proteasome inhibitors would
cause an accumulation of ubiquitinated viral proteins,
which would be readily identified by the increased molec-
ular mass, as it has been shown for AAVs (Yan et al.,
2002). However, change in the molecular mass of the
MVM capsid proteins was not detectable in MG132-treated
cells at any of the examined time points after internalization
(Fig. 6B).
It has been previously shown that proteasomes disturb the
infection of AAV-2 and -5 and thus they are considered as
degradative factors for these viruses (Douar et al., 2001; Duan
et al., 2000; Yan et al., 2002). It was therefore interesting to
examine whether the proteasomes, although required for
MVM infection, could still be able to degrade or proteolyt-
ically process a proportion of MVM incoming capsids. To
address this question, the stability of the MVM structural
proteins was examined at various periods of time during the
intracellular trafficking of the virus, in the presence or
absence of MG132. However, as it is shown in Fig. 6B, no
evidence of protein loss or modification was observed, apart
from the natural VP2 cleavage. This result emphasizes that
the proteasome does not represent a degradative factor or a
barrier but an essential part of the infectious pathway of
MVM.
MVM is sensitive to MG132 in different cell lines
The effect of MG132 on MVM infection was examined
in parallel in two different cells lines, the murine A9 and the
human transformed NB324K cells, both permissive for
MVM. The results showed that similarly to A9 cells,
MVM infection was also sensitive to MG132 in NB324K
cells (Fig. 7A).MG132 blocks the infection of CPV but not that of BPV
It has been previously shown that adeno-associated virus
(AAV) infections are not disturbed by proteasome inhib-
itors. On the contrary, under proteasome blocking condi-
tions, AAV nuclear transduction is enhanced. It has been
shown that in cells with active proteasomes, a proportion of
incoming AAV particles are ubiquitinated and degraded
(Douar et al., 2001; Duan et al., 2000; Yan et al., 2002).
We show, however, that MVM incoming capsids are neither
ubiquitinated nor degraded and that proteasome inhibitors
block the nuclear translocation of the virus. These observa-
tions reveal an obvious difference between the cytoplasmic
trafficking of MVM and AAVs. To further study this
intriguing discrepancy, we examined whether the sensitivity
of MVM to proteasome inhibitors is an isolated case within
the parvovirus family. In this way, we investigated the effect
of proteasome inactivation on two other parvoviruses,
canine parvovirus (CPV) and bovine parvovirus (BPV).
We selected these parvoviruses because CPV is closely
related to MVM, and its cytoplasmic trafficking resembles
that of MVM in many aspects, while BPV is distantly
related (Lukashov and Goudsmit, 2001). Interestingly, CPV
infection was also sensitive to MG132. However, BPV
324 (2004) 350–360
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regardless the time that the drug was present in the cells
(Fig. 7B).Discussion
Given the value of parvoviruses as gene delivering
vectors for human therapy, it is crucial to identify the
intracellular factors that enhance or disturb their nuclear
translocation. The 26S proteasome is a large multi-subunit
complex that selectively degrades intracellular proteins. It is
involved in a wide variety of proteolytically mediated
intracellular processes, such as cell cycle progression, apop-
tosis, metabolic regulation, and transcriptional control (Hilt
and Wolf, 2000). An additional function of the proteasome
is the processing of antigens generating peptides for the
major histocompatibility complex (MHC) pathway (Hilt and
Wolf, 2000; Niedermann, 2002; Rock and Goldberg, 1999).
In this way, proteasomes would represent a degradative
pathway and an obstacle for the infection, as it has been
recently shown for adeno-associated viruses, in which a
proportion of AAV-2 and -5 incoming viruses have been
found to be ubiquitinated and degraded (Douar et al., 2001;
Duan et al., 2000; Yan et al., 2002). In these studies, an
enhanced AAV nuclear translocation was observed in the
presence of MG132; however, the mechanisms of this
enhancement were not elucidated. We have previously
shown that differently to AAVs, MVM infection is not
enhanced but disrupted in the presence of proteasome
inhibitors (Ros et al., 2002).
In the present studies, we characterize various aspects of
the MVM-proteasome interplay. We observed that MG132
was fully active against MVM when present at the begin-
ning of the infection and a very limited effect was observed
when present later after infection (Fig. 1). This observation
indicated the involvement of the cytosolic proteasomes at
the level of transport or trafficking of incoming particles
toward the nuclei. This result was confirmed by observing
that in cells with inactive proteasomes, MVM is unable to
penetrate into the nuclei, remaining blocked in the perinu-
clear region (Figs. 3A and B), explaining the reason for the
decreased or total absence of MVM-DNA or protein syn-
thesis under proteasome blocking conditions. It was inter-
esting to observe that in both treated and nontreated cells,
the virus remained intact even 8 h after internalization (Fig.
4B). In case of MG132-treated cells, even at 24 h after
internalization, the capsids remained intact in the perinu-
clear region (Fig. 5B). We know from our previous results
that under similar conditions, viral DNA replication starts
around 8 h after internalization in a population of
asynchronized A9 cell and that both endosomal and protea-
somal drugs are no longer effective if applied 8 h after
internalization. This would indicate that for the bulk of
MVM incoming particles, the endosomal and proteasomal
pathways are concluded by that time. Therefore, we canassume that neither the endosomes nor the proteasomes are
the sites of final uncoating and thus disassembling of the
viral capsids should take place later, at the nuclear pore or
inside the nuclei. This observation would be in agreement
with the results obtained with CPV in which microinjection
of an antibody that recognizes the intact CPV capsid into the
cytoplasm of cells blocks the infection even when injected
8 h after virus inoculation (Vihinen-Ranta et al., 2002). It
has also been shown that AAV-2 can efficiently enter intact
nuclei purified from both permissive and less permissive
cell types and that purified nuclei contain all of the machin-
ery necessary for uncoating (Hansen et al., 2001).
The proteasomes are involved in the proteolytic degra-
dation and processing of many proteins. Therefore, it was
interesting to investigate the possible role of the proteasome
in the proteolytic processing of VP2 to VP3, a natural
cleavage observed during the internalization of MVM or
in the externalization of the N-terminal of VP1. In the
presence of MG132, VP2 was cleaved and the N-terminal
of VP1 was externalized similarly to untreated cells. Thus,
proteasome are not involved in these two events and their
role in MVM infection should be different.
The majority of proteins that target the proteasome are
tagged with polyubiquitin, which serves as a signal for
their degradation. However, there are a limited number of
examples of proteasome-dependent, ubiquitin-independent
degradation of proteins (Asher et al., 2002; Kalejta and
Shenk, 2003; Krappmann et al., 1996; Michalek et al.,
1996; Miller and Pintel, 2001; Sheaff et al., 2000). A
proportion of AAV-2 and -5 incoming viruses are ubiqui-
tinated during the internalization process and degraded
(Douar et al., 2001; Duan et al., 2000; Yan et al., 2002).
Because ubiquitination is a signal to enter the degradative
pathway of the proteasome, it is not surprising that MVM
particles are not ubiquitinated because they are not de-
graded by the proteasome.
The differences observed among AAVs, BPV, CPV, and
MVM regarding proteasome requirement and ubiquitination
would suggest that parvoviruses follow divergent nuclear
translocation strategies. For example, it is known that the
cytoplasmic trafficking of AAVs is fast (Bartlett et al., 2000;
Seisenberger et al., 2001) although that of MVM and other
autonomous parvoviruses, like CPV, is slow (Ros et al.,
2002; Vihinen-Ranta et al., 2002). Recently, several viruses
were found to require active proteasomes. Retroviruses
require the proteasome for budding from cells (Patnaik et
al., 2000; Schubert et al., 2000; Strack et al., 2000), the
human cytomegalovirus for inducing cell cycle progression
(Kalejta and Shenk, 2003; Kalejta et al., 2003), the simian
virus 5 and human parainfluenza virus type 2 for blocking
IFN signaling (Andrejeva et al., 2002; Didcock et al., 1999),
and Epstein–Barr virus and herpes simplex virus 1 for
regulating viral latency (Dantuma and Masucci, 2003;
Eom and Lehman, 2003). Adenovirus requires active pro-
teasomes to promote late gene expression (Corbin-Lickfett
and Bridge, 2003) and coxsackievirus for viral RNA trans-
C. Ros, C. Kempf / Virology 324 (2004) 350–360358cription and protein synthesis (Luo et al., 2003). The
proteasome-MVM interplay described here has a unique
feature, only shared with influenza virus, in that the require-
ment of ubiquitin–proteasome activity is at the early stages
of the infection. It has been recently shown that influenza
virus requires the proteasome for endosomal progression,
and therefore, proteasome inhibitors block the infection
inside endosomal vesicles (Khor et al., 2003). Although
the blocked MVM incoming particles did not colocalize
with EEA1 or Lamp2, we should however consider the
possibility that MVM could be blocked inside an endosomal
vesicle that is not recognized by the antibodies used in this
study. Regarding this question, a more detailed characteriza-
tion of the ring-like aggregates is anticipated. Interestingly,
the exposure of the N-terminal of VP1, which is required for
endosomal escape and nuclear penetration (Tullis et al.,
1993; Vihinen-Ranta et al., 1997, 2002; Zadori et al.,
2001), was not affected by proteasome inhibitors. Hence,
there should be additional factor(s), besides the N-VP1
exposition, which are required for MVM nuclear transloca-
tion and which are dependent on the proteasome activity. The
results obtained with other parvoviruses reveal divergent
strategies of infection, where some parvoviruses like MVM
and CPV require the activity of the ubiquitin–proteasome
machinery, although other parvoviruses like AAV and BPV
do not require such activity or it is even detrimental for the
infection.Materials and methods
Cells and viruses
Mouse A9 fibroblast (Littlefield, 1964; Tattersall and
Bratton, 1983) and human NB324K cells (Shein and
Enders, 1962) were propagated in Dulbecco’s modified
Eagle’s medium (DMEM). Canine A72 cells were propa-
gated in L-15 Leibovitz medium and bovine turbinate (BT)
cells were maintained in minimal essential medium (MEM).
The medium was supplemented with 10% of heat inacti-
vated fetal calf serum (FCS), except for BT cells that were
maintained with 10% horse serum. Virus stocks were
titrated by using a standard TCID50 technique and stored
at 70 jC. MVM empty capsids, and DNA-full virions
were prepared from MVM stocks as previously described
(Hernando et al., 2000).
Chemicals and antibodies
MG132, epoxomicin, and aclarubicin were obtained
from Calbiochem (La Jolla, CA), and a-chymotrypsin
(TLCK-treated) was purchased from Sigma (St. Louis,
MS). Rabbit anti-VPs (polyclonal against MVM structural
proteins) and mouse anti-capsid (monoclonal against intact
capsids, clone B7) were kindly provided by J.M. Almendral
(Lombardo et al., 2000; Lopez-Bueno et al., 2003). Rabbitantibody against the N-terminal of VP1 was kindly provided
by P. Tattersall (Cotmore et al., 1999). Mouse anti-giantin
(monoclonal antibody against Golgi) was kindly provided
by H.-P. Hauri. Mouse monoclonal against ubiquitin (P4D1)
was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Mouse antibody against early endosomes (EEA1) was
obtained from BD Transduction Laboratories (Lexington,
KY). Rat antibody against late endosomes or lysosomes
(Lamp2) was purchased from Calbiochem.
Real-time PCR
Quantitative PCR was used to detect and quantify viral
DNA sequences. Primers for MVM-DNA amplification were
forward: 5V-GACGCACAGAAAGAGAGTAACCAA-3V
(nucleotide position, 231–254) and reverse: 5V-CCAAC-
CATCTGCTCCAGTAAACAT-3V (nucleotide position,
709–732). Primers for CPV-DNA amplification were for-
ward: 5V-CGCCAAAAAGCAAGTACAAAC-3V (nucleo-
t i d e p o s i t i o n , 5 2 3 – 5 4 3 ) a n d r e v e r s e : 5 V-
ACCGAACAAAGAGTCACCAAC-3V (nucleotide posi-
tion, 745–765). Primers for BPV-DNA amplification were
forward: 5V-CCATCTTG-GTCCTACGTCATC-3V (nucleo-
tide position, 390–410) and reverse: 5V-TGGCTCCAG-
CAACTAAATGTC-3V (nucleotide position, 651–671).
Amplification and real-time detection of PCR products
was performed on the DNA samples using the Lightcycler
system (Roche Diagnostics, Rotkreuz, Switzerland) with
SYBR Green (Roche). A melting curve analysis was per-
formed for specific product identification. PCR was per-
formed using the FastStart DNA SYBR Green kit (Roche)
following the manufacturer’s instructions. Cycling condi-
tions consisted of a step at 95 jC for 10 min to activate the
polymerase enzyme followed by 35 cycles with the follow-
ing thermal profile: 94 jC/15 s, 66 jC (MVM-PCR); 61 jC
(CPV and BPV-PCR)/5 s and 72 jC/30 s. As external
standards, the PCR products generated by the above primers
were cloned into the pGEM-T vector (Promega, Madison,
WI) and used in 10-fold dilutions.
To asses the period of time after internalization at which
the cellular proteasomes are required, A9 cells were infected
with MVM and the effect of MG132, added at different
intervals, was evaluated by real-time PCR. A9 cells were
seeded in 12-well plates at 105 cells per well in Dulbecco’s
modified Eagle’s medium supplemented with 10% FCS and
incubated at 37 jC. Twenty-four hours later, cells were
infected at an MOI of 1000 DNA-containing particles/cell in
Dulbecco’s modified Eagle’s medium without FCS fetal calf
serum for 30 min at 4 jC. The cells were subsequently
washed to remove unbound virus and further incubated at
37 jC in the presence of MG132 (25 AM). At different
intervals, as specified in Fig. 1, cells were washed to remove
MG132 and further incubated until 18 h. At the end of the
incubation period, cells were trypsinized and collected by
low-speed centrifugation. Total DNAwas extracted from the
cell pellet by using the DNeasy tissue kit (Qiagen, Valencia,
C. Ros, C. Kempf / Virology 324 (2004) 350–360 359CA). Control cells were similarly infected with MVM but
did not receive any inhibitor, instead, they were treated with
DMSO (the diluent used for MG132). Negative controls
were included which were neither infected nor treated with
any compound.
Immunofluorescence
A9 cells (105) were seeded onto coverslips inside 12-well
plates. After 24 h, the cells were infected with MVM at 4 jC
at an MOI of 5000 DNA-containing particles/cell. At
different times, cells were washed with PBS and fixed in
a solution of methanol–acetone (1:1) for 6 min at 20 jC.
Cells were subsequently washed two times with PBS. A
blocking solution of PBS–10% goat serum was added for
20 min and the cells were washed with PBS two times. Cells
were incubated with antibodies in PBS containing 2% goat
serum and incubated at RT for 30–45 min. The cells were
subsequently washed several times in PBS and the second-
ary antibodies coupled with rhodamine or FITC were added
for 30–45 min in PBS containing 2% goat serum. After
final washings in PBS, the cells were rinsed in water and
ethanol and mounted with mowiol (Calbiochem) containing
30 mg/ml of Dabco (Sigma), as antifading agent. The cells
were examined by fluorescence microscopy. Images were
captured with the proper filter sets and a 100 oil immer-
sion objective.
Detection of viral structural proteins and ubiquitin
A9 cells (105) were infected and treated with drugs as
specified in the figure legends. At various times after
infection, cells were lysed in protein loading buffer. Proteins
were resolved by sodium dodecyl sulfate (SDS)–10%
polyacrylamide gel electrophoresis (PAGE). After transfer
to a PVDF membrane, the blot was probed with a rabbit
anti-VPs polyclonal antibody (1:2000 dilution, kindly pro-
vided by J. Almendral) or a mouse monoclonal against
ubiquitin (P4D1, 1:200 dilution) followed by a horseradish
peroxidase-conjugated secondary antibody (1:20000 dilu-
tion). The proteins were visualized with a chemilumines-
cence system (Pierce, Rockford, IL).Acknowledgments
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